Governance questions healthcare AI vendors should make easier to answer

Governance is not one policy page. It is the practical distribution of decision rights, oversight, monitoring, escalation and responsibility across the product lifecycle.

Governance becomes real through decisions

Words such as responsible AI, human oversight and continuous monitoring are common. They matter, but they do not tell a buyer who approves use, who reviews performance, who can override an output, who investigates a concern or who has the authority to stop the system.

NIST describes AI risk management as a way to incorporate trustworthiness considerations into the design, development, use and evaluation of AI systems. WHO guidance similarly places ethics and governance around the full set of actors affected by AI in health. For a buyer, those principles become actionable only when they are translated into decision rights and operating responsibilities.

The governance questions behind a complex purchase

Who owns approval and oversight? Which decisions remain with humans? How are model changes reviewed? What happens when performance declines? How are bias and population fit assessed? How are incidents escalated? Which responsibilities belong to the vendor, and which remain with the health organisation?

No public page can answer every organisation-specific question. But a vendor can make its own governance model legible and identify where buyer governance must take over.

Governance evidence has levels

Public evidence can explain intended use, human oversight, general monitoring, known limitations and the company’s responsibility model. Controlled evidence can provide governance procedures, validation summaries, change-control detail and incident processes. NDA material may cover sensitive technical or contractual information. Buyer-specific work defines local decision rights, committees, thresholds and escalation.

The value of this structure is not to publish everything. It is to prevent governance from becoming a vague promise followed by a generic contact form.

Governance affects more than compliance

A governance question may begin with compliance but affect clinical safety, workflow, procurement, executive accountability and commercial risk. For example, a model-update process affects technical validation, clinical review, contract notification and the internal champion’s ability to explain whether the original decision still holds.

This is why governance evidence should be mapped across stakeholders rather than owned by one policy page.

What companies can do

Build a governance-to-decision crosswalk. For each governance domain, identify the stakeholder question, the evidence the company can provide, the access level, the responsible owner, the decision it supports and what remains buyer-specific.

Design cross-functional decision meetings for the hardest questions. A model-change meeting, for example, should specify participants, evidence inputs, questions to resolve, required output and the decision gate that follows. This turns governance from a list of commitments into a repeatable decision process.

The Archoric perspective

Archoric does not certify that a company’s governance is legally, clinically or operationally sufficient. It assesses whether the available evidence makes the governance structure understandable, bounded and usable for the stakeholders who must evaluate it.

Apply this: Use the Decision Resources library to map the questions, evidence routes and unresolved decision work in your own company. Open the library ↗

Sources

Company-specific application

What does your public evidence currently enable stakeholders to understand?

The Proof-to-Decision™ Assessment applies a governed review to the company’s actual evidence, stakeholder questions and public routes.

Explore the Assessment